Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer

Background The mechanisms underlying the favourable prognosis of androgen receptor (AR) expression in breast cancer are unknown. Methods The associations between the 21-gene recurrence score (RS), AR, grade, mitotic score, Ki-67 and estrogen receptor (ER) and progesterone receptor (PgR) expression were explored in sequential women with lymph node-negative, ER-positive and HER2-negative breast cancer. Statistical significance of this exploratory study was defined as p<0.10. Results Analysis comprised 70 women. Most tumours had high AR expression (97% had scores >3). Median RS was 15 (range 1–53). AR expression showed a minimally significant positive correlation with ER (R=0.37), but no correlation with Ki-67 (R=−0.18). In univariable analysis, AR (p=0.01), ER (p<0.001) and PgR (p<0.001) had significant negative associations with RS. Ki-67 (p=0.16), grade (p=0.40) and mitotic score (p=0.23) showed no association with RS. Multivariable analysis showed similar associations. Conclusions AR is associated with lower RS, but not with Ki-67.

[1]  R. A. Blanchard,et al.  Tumor grade, Ki 67%, and relantionship with the 21-gene recurrence score assay in early breast cancer tumors. , 2014 .

[2]  P. Neven,et al.  Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC). , 2014 .

[3]  D. Dabbs,et al.  Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis , 2013, Modern Pathology.

[4]  Harald Frick,et al.  How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.

[5]  C. Hudis,et al.  Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). , 2012 .

[6]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[7]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[8]  W. Miller,et al.  Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score , 2011, British Journal of Cancer.

[9]  G. Colditz,et al.  Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.

[10]  S. Hilsenbeck,et al.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[11]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[12]  Li Jia,et al.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.

[13]  K. Gwin,et al.  Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score , 2009, International journal of surgical pathology.

[14]  B. Ramaswamy,et al.  Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant. , 2009 .

[15]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[16]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[17]  K. Wernecke,et al.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer , 2006, Virchows Archiv.

[18]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[19]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Buzdar,et al.  Estrogen receptor: A prognostic factor in breast cancer , 1981, Cancer.

[21]  I. Tannock,et al.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[22]  R. Heidel,et al.  Prognostic Value of Breast Cancer Subtypes, Ki‐67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian Women , 2013, The breast journal.

[23]  Yan Li,et al.  High Ki-67 expression is a poor prognostic indicator of 5-year recurrence free survival in patients with invasive breast cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[24]  A. Feinstein,et al.  Indexes and boundaries for "quantitative significance" in statistical decisions. , 1990, Journal of clinical epidemiology.